Key Moments
395 – Brain lipidology: understanding APOE, cholesterol homeostasis, Alzheimer’s disease, & more
Peter Attia MDWant to know something specific about what's covered?
We've already dissected every moment. Ask and we will deliver (with timestamps).
Key Moments
The brain's cholesterol system is almost entirely separate from the body's, with APOE lipoproteins, not APOB, facilitating essential cholesterol transport to neurons via specialized brain HDLs, and APOE4 genotype disrupts this, increasing Alzheimer's risk.
Key Insights
The brain's cholesterol pool (approx. 140 grams) is vastly larger than the liver's (3-5 grams) and operates independently of peripheral lipid transport systems.
Brain cholesterol is primarily synthesized endogenously and is crucial for myelin sheath formation by oligodendrocytes and neuronal cell membranes.
In the brain, APOE-containing lipoproteins, functionally similar to peripheral HDLs but distinct in their protein composition, are responsible for cholesterol transport to neurons.
The APOE4 genotype is associated with a 2-12 fold increased risk of Alzheimer's disease, linked to dysfunctional APOE4-containing brain HDLs and disrupted cholesterol transport into neurons.
24S-hydroxy cholesterol in plasma is a potential biomarker for brain health, with its presence indicating excess cholesterol in neurons that the brain is attempting to excrete.
Statins are the only lipid-lowering drugs that can penetrate the blood-brain barrier and influence brain cholesterol synthesis, with no clear evidence of harm and some suggesting reduced Alzheimer's incidence.
Peripheral lipid transport: A primer on cholesterol handling
Cholesterol is vital for cell membranes and hormone production, with each cell capable of synthesizing its own. Excess cholesterol can be toxic, prompting cellular export into the bloodstream. Since lipids are hydrophobic, they are transported via lipoproteins, which are protein-lipid complexes. High-density lipoproteins (HDLs), characterized by APOA1 protein, are formed as cells efflux cholesterol. The liver and intestine produce larger apoB-containing lipoproteins, such as very-low-density lipoproteins (VLDLs) and low-density lipoproteins (LDLs), which are primarily triglyceride and cholesterol carriers, respectively. LDLs have a long plasma residence time (3-5 days) and are cleared by the liver via LDL receptors. While often perceived as delivering cholesterol to cells, a primary function of LDLs is actually reverse cholesterol transport, returning cholesterol to the liver, and HDL's role in this is often indirect, transferring cholesterol to LDLs. Importantly, the small amount of cholesterol in plasma (e.g., a few grams in 200 mg/dL total cholesterol) is minuscule compared to the total body's cholesterol stores within cells (hundreds of grams).
The brain's independent cholesterol system
The brain's cholesterol system operates almost entirely independently of the periphery, with APOB-containing lipoproteins too large to cross the blood-brain barrier. The brain is the largest cholesterol storage organ, containing approximately 140 grams, significantly more than the liver's 3-5 grams. This high concentration is due to the brain's extensive need for cholesterol for cell membranes, particularly in neurons, and for the production of myelin by oligodendrocytes, which sheathes nerve axons. Cholesterol synthesis begins in fetal development and continues throughout life, though neuronal synthesis decreases around age 10 as they rely on neighboring glial cells (astrocytes and oligodendrocytes) for supply due to the high ATP cost of synthesis. This brain-specific system highlights that peripheral lipid levels have no direct bearing on brain cholesterol levels.
APOE-mediated lipid transport in the brain
Within the brain's interstitial space, cholesterol is transported between cells via APOE-containing lipoproteins, which are functionally analogous to peripheral HDLs but have a different core protein. Astrocytes synthesize cholesterol, convert it to desmosterol, and package it into APOE-containing particles secreted into the matrix. These brain HDLs have a density similar to plasma HDLs but are composed primarily of APOE. Neurons possess LDL receptors, which in the periphery bind APOB, but in the brain, these receptors selectively bind APOE-containing lipoproteins because APOB is absent. This is why researchers suggest calling the receptor the 'APOE/APOB receptor.' The liver also has LDL receptors that bind APOB, and additionally, uses LDL receptor-related protein 1 (LRP1) which specifically binds APOE on chylomicrons and VLDLs, facilitating their clearance. Scavenger receptor B1 in neurons also recognizes APOE.
The influence of APOE genotype on brain health and Alzheimer's risk
The APOE gene has several isoforms (E2, E3, E4), with E3 being the most common ('wild type'). The APOE4 isoform, present in the APOE3/E4 and APOE4/E4 genotypes, is associated with a substantially increased risk of Alzheimer's disease. Individuals with one copy of APOE4 have a 2-3 times higher risk, while those with two copies (APOE4/E4) have an 8-12 times higher risk compared to E3/E3 individuals. This increased risk is linked to APOE4's reduced efficacy in cholesterol transport and neuronal uptake, leading to impaired cholesterol homeostasis within neurons. This disruption can affect cell membrane integrity, influence the processing of amyloid precursor protein (APP) and promote the production of more toxic beta-amyloid 42 species over less toxic beta-amyloid 40.
Cholesterol metabolism and biomarkers in the brain
Excess cholesterol accumulation in neuronal cell membranes can impair function and lead to neuronal death. To manage this, neurons can convert cholesterol into 24S-hydroxy cholesterol, a more water-soluble oxysterol that can cross the blood-brain barrier and be excreted into the plasma. This oxysterol is then transported to the liver for further processing and eventual elimination. Elevated levels of 24S-hydroxy cholesterol in plasma serve as a potential biomarker for brain cholesterol overload and neuronal dysfunction, suggesting increased risk or presence of neurodegenerative processes. Another biomarker, desmosterol (an intermediate in one cholesterol synthesis pathway), found in cerebrospinal fluid and plasma, also correlates with brain cholesterol synthesis and has been linked to cognitive impairment.
Pharmacological interventions: Statins and beyond
Statins are the only class of lipid-lowering drugs capable of crossing the blood-brain barrier, regardless of whether they are lipophilic or hydrophilic, and can inhibit cholesterol synthesis in the brain. While often prescribed for peripheral atherosclerosis, studies suggest potential benefits for brain health, with meta-analyses showing no harm and some indicating a reduced incidence of Alzheimer's disease or cognitive decline. This is hypothesized to be due to a reduction in excessive cholesterol synthesis in neurons. However, over-suppression could theoretically lead to 'brain fog,' an anecdotal side effect. Ezetimibe, which inhibits cholesterol absorption in the gut, can also have metabolites that enter the brain and may offer cognitive benefits, though this is less established. Omega-3 fatty acids (EPA and DHA) are crucial for brain cell membrane health, though robust randomized controlled trials linking their levels to specific brain health outcomes are limited, with evidence primarily observational.
Emerging therapies and future directions
Inhibitors of the proprotein convertase subtilisin/kexin type 9 (PCSK9) enzyme, such as obicetrapib, are showing promise. Genetic studies have indicated that loss-of-function mutations in PCSK9 are associated with reduced Alzheimer's risk. Mechanistically, PCSK9 inhibitors may increase APOA1 and potentially generate smaller, more functional HDL particles that can enter the brain. Preliminary data from the Broadway trial suggests obicetrapib may positively influence Alzheimer's biomarkers like phosphorylated tau and amyloid ratios. Further clinical trials are planned to investigate its impact on cognitive function and Alzheimer's progression, particularly in high-risk individuals like APOE4 carriers, aiming to intervene early in the disease process.
Mentioned in This Episode
●Supplements
●Companies
●Drugs & Medications
●Studies Cited
●Concepts
●People Referenced
Common Questions
Cholesterol, being hydrophobic, is transported in the plasma by lipoproteins. These are particles with a lipid core and a protein exterior. Key lipoproteins include APO A1 (for HDLs) and ApoB (for VLDLs and LDLs), which shuttle cholesterol and triglycerides throughout the body.
Topics
Mentioned in this video
Host of The Drive podcast and co-discussant on brain lipidology. He emphasizes the importance of understanding the peripheral and central nervous system's distinct cholesterol handling.
Guest on The Drive podcast, a lipidologist, who explains the intricacies of cholesterol metabolism in the body and brain.
A researcher mentioned in relation to Peter Attia's podcasts on HDL functionality.
A neurologist colleague whose anecdotal belief is that Ezetimibe might offer cognitive benefits in patients, in addition to controlling ApoB.
A neurologist colleague whose anecdotal belief is that Ezetimibe might offer cognitive benefits in patients, in addition to controlling ApoB.
A researcher who has conducted studies showing a correlation between omega-3 index, brain size (e.g., in the hypothalamus), and neurological outcomes.
A friend and experienced trialist who is driving many studies in the field of lipidology and brain health.
A friend and experienced trialist who is driving many studies in the field of lipidology and brain health.
A structural protein of high-density lipoproteins (HDL) in the periphery, involved in accepting cholesterol from cells. It can cross the blood-brain barrier and combine with brain APOE particles.
A receptor on liver cells that binds to ApoB-containing lipoproteins (primarily LDL) and pulls them into the liver for digestion and processing. Neurons also express these receptors, but they bind APOE in the brain.
A receptor that binds to HDL and delipidates it. In the brain, it can recognize ApoE and facilitates the entry of ApoA1 or small dense HDLs across the blood-brain barrier.
A penultimate sterol in one of the cholesterol synthesis pathways. In the brain, desmosterol levels in plasma highly correlate with cerebral spinal fluid desmosterol, making it a marker for brain cholesterol production.
A rare APOE genotype associated with a lower risk of Alzheimer's disease compared to APOE3 and APOE4, due to its more functional APOE protein isoform.
The 'wild type' APOE genotype, present in about 55% of the population, considered the reference for Alzheimer's risk.
An APOE genotype, with one or two copies, that significantly increases the risk of Alzheimer's disease because it codes for a dysfunctional APOE protein isoform in the brain, disrupting cholesterol transport to neurons.
A protein located in the cell membrane that, when cholesterol balance is disrupted, can be cleaved by beta and gamma secretases to produce injurious amyloid-beta 42, a hallmark of Alzheimer's disease.
A peptide produced from Amyloid Precursor Protein; its accumulation in the brain (especially the 42 form) is a key feature of Alzheimer's disease, influenced by cholesterol levels in neuronal cell membranes.
An oxysterol produced by neurons to excrete excess cholesterol. Its levels in plasma serve as a biomarker for brain health; increased levels suggest neuronal danger or impaired cholesterol regulation, while statins may reduce its presence.
A measure of omega-3 fatty acids (EPA and DHA) in red blood cell membranes. Low levels are associated with increased sudden death and atherosclerotic heart disease.
A dietary pattern that was shown in the Predimed study to be superior to a low-fat diet for primary prevention of cardiovascular events.
A class of drugs primarily used to lower ApoB/LDL cholesterol in the periphery, which can also cross the blood-brain barrier and inhibit cholesterol synthesis in the brain. They have shown neutrality or improvement in cognitive impairment and Alzheimer's disease.
A drug that works in the gut to block cholesterol absorption. Although it cannot cross the blood-brain barrier directly, its metabolite, ezetimibe-glucuronide, can, potentially offering cognitive benefits and reducing inflammation in the brain.
A recent CETP inhibitor primarily aimed at reducing ApoB and major adverse cardiovascular events (MACE). Early data from the Broadway trial suggests it favorably impacts Alzheimer's biomarkers, potentially by increasing APOA1 and protective HDL species in the brain.
An omega-3 fatty acid, ingested through diet or supplements, that is important for brain health. It can be delivered to the brain as a lysophospholipid and is integral to cell membrane health.
An omega-3 fatty acid, ingested through diet or supplements, that is abundant and critically important for brain health. Like EPA, it is delivered to the brain as a lysophospholipid and supports cell membrane integrity.
More from Peter Attia MD
View all 334 summaries
135 min381‒Alzheimer’s disease in women: how hormonal transitions impact the brain, new therapies, & more
9 minIs Industrial Processing the Real Problem With Seed Oils? | Layne Norton, Ph.D.
13 minCooking with Lard vs Seed Oils | Layne Norton, Ph.D.
146 min380 ‒ The seed oil debate: are they uniquely harmful relative to other dietary fats?
Ask anything from this episode.
Save it, chat with it, and connect it to Claude or ChatGPT. Get cited answers from the actual content — and build your own knowledge base of every podcast and video you care about.
Get Started Free